The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer
Open accessAbstract
Background Phase III randomized, clinical trials (RCTs) assess clinically important differences in end points that reflect benefit to patients. Here, we evaluate the quality of reporting of the primary end point (PE) and of toxicity in RCTs for breast cancer.Methods PUBMED was searched from 1995 to 2011 to identify RCTs for breast cancer. Bias in the reporting of the PE and of toxicity was assessed using pre-designed algorithms. Associations of bias with the Journal Impact Factor (JIF), changes in the PE compared with information in ClinicalTrials.gov and funding source were evaluated.Results Of 164 included trials, 33% showed bias in reporting of the PE and 67% in the reporting of toxicity. The PE was more likely to be reported in the concluding statement of the abstract when significant differences favoring the experimental arm were shown; 59% of 92 trials with a negative PE used secondary end points to suggest benefit of experimental therapy. Only 32% of articles indicated the frequency of grade 3 and 4 toxicities in the abstract. A positive PE was associated with under-reporting of toxicity.Conclusion Bias in reporting of outcome is common for studies with negative PEs. Reporting of toxicity is poor, especially for studies with positive PEs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other methodological systematic reviews focusing on two-arm parallel-group RCTs with nonstatistically significant primary outcomes in specific medical fields found consistent results (48–54).”
From Misrepresentation and distortion of research in biomedical literature (2018) · cites this paper as [48]
In the citing paper
“Overestimating or overstating the benefits from new intervention can cause harm: it confounds public policy decision making [29], undermines the credibility of oncology research reporting [26,29,30], harms patients who choose to undertake treatments based on exaggerated expectations that may subject them to either risk of adverse effects, inconvenience or substantial personal costs [26,28] and, in”
Citations
Cites
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020124 · Cited by 10,505
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · CHANCE · doi:10.1080/09332480.2005.10722754 · Cited by 4,702 · cited 1×
“Selection bias can affect not only the interpretation of the trial itself but also the interpretation of subsequent systematic reviews or overviews, producing inaccurate summaries of research [2, 9] and misrepresentation of toxicity [10].”
BackgroundSiegel, R., Ward, E., Brawley, O., & Jemal, A. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20121 · Cited by 4,070
Chan, A.-W., Hróbjartsson, A., Haahr, M. T., Gøtzsche, P. C., & Altman, D. G. (2004) · JAMA · doi:10.1001/jama.291.20.2457 · Cited by 1,845 · cited 3×
“The pharmaceutical industry is increasingly influential in clinical trial sponsorship with data showing an increase in industry sponsorship of phase III RCTs from 24 to 72% over a 30 year period [3, 19, 20].”
BackgroundResultBetter Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
Ioannidis, J. P. A., Evans, S. J. W., Gøtzsche, P. C., O'Neill, R. T., Altman, D. G., Schulz, K., Moher, D., & for the CONSORT Group* (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00009 · Cited by 1,593 · cited 1×
“Guidelines such as Consolidated Standards of Reporting Trials can improve the quality of reporting of clinical trials [6].”
BackgroundSystematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias
Dwan, K., Altman, D. G., Arnaiz, J. A., Bloom, J., Chan, A.-W., Cronin, E., Decullier, E., Easterbrook, P. J., Von Elm, E., Gamble, C., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003081 · Cited by 1,546 · cited 3×
“Such trials provide the gold standard to evaluate the efficacy and toxicity of new drugs before approval by regulatory authorities [2, 3].”
BackgroundGianni, L., Eiermann, W., Semiglazov, V., Manikhas, A., Lluch, A., Tjulandin, S., Zambetti, M., Vazquez, F., Byakhow, M., Lichinitser, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61964-4 · Cited by 1,255
Kirkham, J. J., Dwan, K. M., Altman, D. G., Gamble, C., Dodd, S., Smyth, R., & Williamson, P. R. (2010) · BMJ · doi:10.1136/bmj.c365 · Cited by 1,133 · cited 1×
“Trial registration does not necessarily remove bias in reporting outcome, although it does make it easier to detect [18].”
BackgroundCortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Boutron, I. (2010) · JAMA · doi:10.1001/jama.2010.651 · Cited by 842 · cited 1×
“The pharmaceutical industry is increasingly influential in clinical trial sponsorship with data showing an increase in industry sponsorship of phase III RCTs from 24 to 72% over a 30 year period [3, 19, 20].”
Background
Research works printed but not linked: 1
- Ocana, 2011, When are ‘positive’ clinical trials in oncology truly positive?, J Natl Cancer Inst, 103, 16, 10.1093/jnci/djq463 · DOI · Paper page
Cited by
Reducing waste from incomplete or unusable reports of biomedical research
Glasziou, P., Altman, D. G., Bossuyt, P., Boutron, I., Clarke, M., Julious, S., Michie, S., Moher, D., & Wager, E. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62228-x · Cited by 1,319
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818
“Overestimating or overstating the benefits from new intervention can cause harm: It confounds public policy decision making [29], undermines the credibility of oncology research reporting [26, 29, 30], harms patients who choose to undertake treatments based on exaggerated expectations that may subject them to either r…”
BackgroundBooth, C. M., & Tannock, I. F. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.725 · Cited by 469
“…therapy is providing benefit to patients when there is no difference in the primary outcome measure as compared with the control arm and/or increased toxicity associated with the new treatment (Ohorodnyk et al, 2009; Boutron et al, 2010; Altwairgi et al, 2012; Vera-Badillo et al, 2013).”
BackgroundSelf-citationBoutron, I., Altman, D. G., Hopewell, S., Vera-Badillo, F., Tannock, I., & Ravaud, P. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.7503 · Cited by 368
Self-citation‘Spin’ in published biomedical literature: A methodological systematic review
Chiu, K., Grundy, Q., & Bero, L. (2017) · PLOS Biology · doi:10.1371/journal.pbio.2002173 · Cited by 317
Metadata
- Authors
- Vera-Badillo, F. E., Shapiro, R., Ocana, A., Amir, E., & Tannock, I. F.
- Affiliations
- University of Toronto (CA)
- Corresponding author
- Tannock, I.F.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 24
- Issue
- 5
- Pages
- 1238-1244
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2120241552
- Cited by
- 117
- References
- 27
- Citations by year
- 2026: 3 · 2025: 1 · 2023: 3 · 2022: 4 · 2021: 8 · 2020: 8 · 2019: 13 · 2018: 11 · 2017: 8 · 2016: 13 · 2015: 13 · 2014: 14 · 2013: 18
- FWCI
- 21.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 2442 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- breast cancer, reporting bias, primary endpoint, adverse event reporting, randomized controlled trials, women, abstract reporting, negative trial results, funding disclosure
- MeSH terms
- Algorithms, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Research Design, Observer Variation, Bias, Randomized Controlled Trials as Topic, Journal Impact Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. https://app.cochat.ai/papers/10.1093/annonc/mds636
- The paper
- Vera-Badillo, F. E., Shapiro, R., Ocana, A., Amir, E., & Tannock, I. F. (2013). Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Annals of Oncology. https://doi.org/10.1093/annonc/mds636
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.